[go: up one dir, main page]

NO982556L - Behandling av CNS-virkningene av HIV med VX-478, alene eller i kombinasjon med AZT eller 3TC - Google Patents

Behandling av CNS-virkningene av HIV med VX-478, alene eller i kombinasjon med AZT eller 3TC

Info

Publication number
NO982556L
NO982556L NO982556A NO982556A NO982556L NO 982556 L NO982556 L NO 982556L NO 982556 A NO982556 A NO 982556A NO 982556 A NO982556 A NO 982556A NO 982556 L NO982556 L NO 982556L
Authority
NO
Norway
Prior art keywords
azt
hiv
alone
treatment
combination
Prior art date
Application number
NO982556A
Other languages
English (en)
Other versions
NO317837B1 (no
NO982556D0 (no
Inventor
Pravin Ramsewak Chaturvedi
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO982556D0 publication Critical patent/NO982556D0/no
Publication of NO982556L publication Critical patent/NO982556L/no
Publication of NO317837B1 publication Critical patent/NO317837B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO19982556A 1995-12-05 1998-06-04 Anvendelse av forbindelse for fremstilling av et medikament for a inhibere et aspartylproteaseavhengig virus NO317837B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/567,199 US5646180A (en) 1995-12-05 1995-12-05 Treatment of the CNS effects of HIV
PCT/US1996/019447 WO1997020554A1 (en) 1995-12-05 1996-12-05 Treatment of the cns effects of hiv with vx-478, alone or in combination with azt or 3tc

Publications (3)

Publication Number Publication Date
NO982556D0 NO982556D0 (no) 1998-06-04
NO982556L true NO982556L (no) 1998-06-04
NO317837B1 NO317837B1 (no) 2004-12-20

Family

ID=24266147

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19982556A NO317837B1 (no) 1995-12-05 1998-06-04 Anvendelse av forbindelse for fremstilling av et medikament for a inhibere et aspartylproteaseavhengig virus

Country Status (23)

Country Link
US (1) US5646180A (no)
EP (1) EP0866696B1 (no)
JP (1) JP2000501713A (no)
KR (1) KR19990071750A (no)
CN (1) CN1203530A (no)
AP (1) AP864A (no)
AT (1) ATE279922T1 (no)
AU (1) AU722850B2 (no)
BR (1) BR9611861A (no)
CA (1) CA2238471A1 (no)
CZ (1) CZ291994B6 (no)
DE (1) DE69633680T2 (no)
ES (1) ES2231828T3 (no)
HU (1) HUP9903673A3 (no)
NO (1) NO317837B1 (no)
NZ (1) NZ324603A (no)
OA (1) OA10691A (no)
PL (1) PL187747B1 (no)
PT (1) PT866696E (no)
RU (1) RU2203658C2 (no)
UA (1) UA61902C2 (no)
WO (1) WO1997020554A1 (no)
ZA (1) ZA9610139B (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107499A (en) * 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
AU727983B2 (en) * 1996-06-25 2001-01-04 Glaxo Group Limited Combinations comprising VX478, zidovudine, FTC and/or 3TC for use in the treatment of HIV
AU723877C (en) * 1996-06-25 2001-08-23 Glaxo Group Limited Combinations comprising VX478, zidovudine and/or 1592U89 for use in the treatment of HIV
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
BR9809124A (pt) * 1997-05-17 2000-08-01 Glaxo Group Ltd Combinação, formulação, farmacêutica, processo para o tratamento de uma infecção por hiv em um animal, infectado, uso de (-)-(1s, 4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-cicl openteno-1-metanol, e, pacote de paciente
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US6576231B2 (en) * 1997-09-12 2003-06-10 Schering Ag Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6309632B1 (en) * 1998-04-28 2001-10-30 Immunex Corporation Methods for treating HIV-infected patients by administering GM-CSF
US20090197827A1 (en) * 1998-05-29 2009-08-06 Dunn Ben M Combination Therapy for Treatment of FIV Infection
US6875773B1 (en) * 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
EP1244670B1 (en) 1999-12-21 2006-03-08 MGI GP, Inc. Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
ATE387169T1 (de) * 2000-10-16 2008-03-15 Conor Medsystems Inc Expandierbare medizinische vorrichtung zum zuführen eines heilmittels
AU2002303164A1 (en) 2001-03-23 2002-10-08 Protarga, Inc. Fatty amine drug conjugates
WO2002076404A2 (en) * 2001-03-23 2002-10-03 Protarga, Inc. Fatty alcohol drug conjugates
CA2477088A1 (en) 2002-02-22 2003-10-02 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
HRP20070078A2 (hr) 2004-07-27 2007-05-31 Gilead Sciences Fosfonatni analozi spojeva koji inhibiraju hiv
WO2006078876A2 (en) * 2005-01-20 2006-07-27 University Of Rochester Compositions and methods relating to mitochondrial hyperpolarization in neurological disease
EP1976976A4 (en) * 2005-12-23 2010-12-15 Univ Rochester TREATMENT OF NEURO-AIDS USING INHIBITORS OF GLYCODY SYNTHASE KINASE (GSK) -3
CN101421234A (zh) * 2006-04-19 2009-04-29 艾博特股份有限两合公司 适于治疗对5-羟色胺5ht6受体调节有反应的病症的杂环芳基砜
SG172060A1 (en) 2008-12-09 2011-07-28 Gilead Sciences Inc Modulators of toll-like receptors
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
CN112426278A (zh) 2014-02-28 2021-03-02 阿坦斯医疗保健产品公司 具有多层折叠吸收芯的吸收性用品
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
CN113577081A (zh) 2014-07-11 2021-11-02 吉利德科学公司 用于治疗hiv的toll样受体调节剂
JP2018527366A (ja) 2015-09-15 2018-09-20 ギリアード サイエンシーズ， インコーポレイテッド ＨＩＶを処置するためのｔｏｌｌ様レセプターのモジュレーター
WO2018112229A1 (en) 2016-12-14 2018-06-21 Eam Corporation Absorbent laminates, absorbent cores and disposable articles utilizing the absorbent laminates, and related methods
PL3801424T3 (pl) 2018-05-28 2025-06-09 Attends Healthcare Products, Inc. Laminat warstwy zapewniającej suchość do wyrobów chłonnych

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0428849A3 (en) * 1989-09-28 1991-07-31 Hoechst Aktiengesellschaft Retroviral protease inhibitors
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
WO1994013629A1 (en) * 1992-12-11 1994-06-23 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease

Also Published As

Publication number Publication date
WO1997020554A1 (en) 1997-06-12
BR9611861A (pt) 1999-05-18
JP2000501713A (ja) 2000-02-15
ES2231828T3 (es) 2005-05-16
PL187747B1 (pl) 2004-09-30
CN1203530A (zh) 1998-12-30
NO317837B1 (no) 2004-12-20
OA10691A (en) 2001-05-04
HUP9903673A2 (hu) 2000-03-28
UA61902C2 (en) 2003-12-15
PL327061A1 (en) 1998-11-23
CZ291994B6 (cs) 2003-07-16
PT866696E (pt) 2005-03-31
ATE279922T1 (de) 2004-11-15
EP0866696B1 (en) 2004-10-20
NZ324603A (en) 2000-08-25
US5646180A (en) 1997-07-08
AP864A (en) 2000-08-11
DE69633680T2 (de) 2006-02-23
AP9801340A0 (en) 1998-09-30
RU2203658C2 (ru) 2003-05-10
AU1148697A (en) 1997-06-27
ZA9610139B (en) 1997-06-17
NO982556D0 (no) 1998-06-04
CZ170898A3 (cs) 1998-09-16
CA2238471A1 (en) 1997-06-12
KR19990071750A (ko) 1999-09-27
DE69633680D1 (de) 2004-11-25
EP0866696A1 (en) 1998-09-30
HUP9903673A3 (en) 2000-08-28
AU722850B2 (en) 2000-08-10

Similar Documents

Publication Publication Date Title
NO982556L (no) Behandling av CNS-virkningene av HIV med VX-478, alene eller i kombinasjon med AZT eller 3TC
MX9200587A (es) ADICCION DE SMO2 COLOIDAL EN LA PRODUCCION DE TiO2 SUBPIGMENTARIO.
AU6924796A (en) 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis c
DE69306796D1 (de) Herstellung von feststoffen im nano-bereich
FI952302L (fi) Pyran-2-onit ja 5,6-dihydropyranonit, jotka ovat käyttökelpoisia HIV:n ja muiden retrovirusten hoidossa
FI970214A0 (fi) Droloksifeenin käyttö sydänverisuonitautien hoitamiseksi
BR9708797A (pt) Processo de preparação de partículas as respectivas partículas e utilização das mesmas
FI950623A7 (fi) Tyydyttymättömät hiilihydraattijohdannaiset, niistä saadut polymeerit ja näiden käyttö
DE69110729D1 (de) Aluminiumpigment und dessen Herstellungsverfahren.
FI971268A7 (fi) Menetelmä 1,3-alkaanidiolien ja 3-hydroksialdehydien valmistamiseksi
AU3262797A (en) Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
DK0808307T3 (da) Bicykliske isothiourinstofderivater, som kan anvendes ved terapi
NO881629L (no) Anvendelse av antigene stoffer ved behandling av lidelseri mage-tarm-kanalen.
NO984760D0 (no) Anvendelse av en osmolytt ved behandling av effekter forÕrsaket av en infeksjon, en inflammasjon eller en immundysfunksjon
FI973184A0 (fi) Kombinaatioterapia HIV-infektiota varten käyttäen HIV-proteaasi-inhibiittoria indinavir ja käänteistranskriptaasi-inhibiittoria 3TC, mahdollisesti yhdessä AZT:n, DDI:n tai DDC:n kanssa
FI912518A0 (fi) Modifiering av kaernan i superledande, en tennkaerna innehaollande materialer med en metallegering.
NO934311L (no) alfa,omega-diarylalkanderivater, deres fremstilling og anvendelse ved behandling av sirkulasjonssykdommer og psykoser
AU3122189A (en) Combinations of polysulfated heparins in the treatment of retrovirus infections
NO996496D0 (no) (S) 2-metylamino-2-fenyl-n-butyl 3,4,5-trimetoksybenzoat samt anvendelse av denne ved behandling av kronisk smerte
FR2702149B1 (fr) Application de la lamotrigine dans le traitement du neuro-sida.
DE68913928D1 (de) Viskoelastischer Dämpfungskörper und das dazugehörige Herstellungsverfahren.
HK1016079A (en) Treatment of the cns effects of hiv with vx-478, alone or in combination with azt or 3tc
FI902364A0 (fi) Anordning foer istaondsaettande av underbacken i en hoppbacke.
DK0866696T3 (da) Behandling af HIV ZNS-effekter med VX-478 alene eller i kombination med AZT eller 3TC
RU97100921A (ru) Антигипоксический комплекс